Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Embeda Uptake In Primary Care Depends On FDA Clearing Marketing Materials, King Says

This article was originally published in The Pink Sheet Daily

Executive Summary

After a warning letter, Embeda sales effort focuses on specialists. Firm does not see franchise threat from generics, although Remoxy will not be refiled until the middle of next year.
Advertisement

Related Content

King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"
King Assures Investors Embeda Marketing Materials Not Lost In DDMAC "Black Hole"
King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?
King Expects Acurox Committee In April: What Are The Standards For Aversion-Based Abuse-Resistance?
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA Warns King Of Warning Letter: Firm Got Head Start On Fixing Embeda Ads
FDA Advisors Question Impact of OxyContin Improvements Due To Generics
Opioids Pending At FDA Held Up By Anti-Abuse Claims, Not REMS Planning

Topics

Advertisement
UsernamePublicRestriction

Register

PS068831

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel